Clinical Trial Update: Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas [Phase 2]

View source ↗

Summary

Phase II study assessing imatinib (Gleevec) in neurofibromatosis type 1 patients with plexiform neurofibromas has completed, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type
• Plexiform Neurofibroma

Drugs mentioned

• Gleevec (Imatinib)

Snippet

Sponsor: Indiana University | Conditions: Neurofibromatosis | Phase 2 | Status: COMPLETED | Results posted: 2016-04-06